{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T07:08:43Z","timestamp":1780643323469,"version":"3.54.1"},"reference-count":22,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,9,1]],"date-time":"2022-09-01T00:00:00Z","timestamp":1661990400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,16]],"date-time":"2022-07-16T00:00:00Z","timestamp":1657929600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2022,9]]},"DOI":"10.1016\/j.jacl.2022.07.005","type":"journal-article","created":{"date-parts":[[2022,7,21]],"date-time":"2022-07-21T02:45:43Z","timestamp":1658371543000},"page":"676-684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"title":["Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia"],"prefix":"10.1016","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5185-3666","authenticated-orcid":false,"given":"Daniel","family":"Gaudet","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Ruzza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Maruff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Schembri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Hamer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3178-9131","authenticated-orcid":false,"given":"Fran\u00e7ois","family":"Mach","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean","family":"Bergeron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Gaudet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie St","family":"Pierre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John J.P.","family":"Kastelein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Kees","family":"Hovingh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Albert","family":"Wiegman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9170-7938","authenticated-orcid":false,"given":"Frederick J.","family":"Raal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9860-6582","authenticated-orcid":false,"given":"Raul D.","family":"Santos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.jacl.2022.07.005_bib0001","doi-asserted-by":"crossref","first-page":"1375","DOI":"10.1194\/jlr.R400004-JLR200","article-title":"Thematic review series: brain lipids. Cholesterol metabolism in the central nervous system during early development and in the mature animal","volume":"45","author":"Dietschy","year":"2004","journal-title":"J Lipid Res"},{"issue":"5","key":"10.1016\/j.jacl.2022.07.005_bib0002","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1161\/01.ATV.0000120374.59826.1b","article-title":"Brain cholesterol: long secret life behind a barrier","volume":"24","author":"Bj\u00f6rkhem","year":"2004","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1016\/j.jacl.2022.07.005_bib0003","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.pharmthera.2016.11.001","article-title":"Intensive LDL-cholesterol lowering therapy and neurocognitive function","volume":"170","author":"Banach","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.jacl.2022.07.005_bib0004","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1007\/s40264-015-0296-6","article-title":"PCSK9 inhibitors and neurocognitive adverse events: exploring the FDA directive and a proposal for N-of-1 trials","volume":"38","author":"Swiger","year":"2015","journal-title":"Drug Saf"},{"key":"10.1016\/j.jacl.2022.07.005_bib0005","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1016\/S0002-9343(00)00353-3","article-title":"Effects of lovastatin on cognitive function and psychological well-being","volume":"108","author":"Muldoon","year":"2000","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.jacl.2022.07.005_bib0006","doi-asserted-by":"crossref","first-page":"823","DOI":"10.1016\/j.amjmed.2004.07.041","article-title":"Randomized trial of the effects of simvastatin on cognitive functioning in hypercholesterolemic adults","volume":"117","author":"Muldoon","year":"2004","journal-title":"Am J Med"},{"key":"10.1016\/j.jacl.2022.07.005_bib0007","unstructured":"FDA drug safety communication: important safety label changes to cholesterol-lowering statin drugs. 2012. Available at https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-important-safety-label-changes-cholesterol-lowering-statin-drugs."},{"issue":"3 Suppl","key":"10.1016\/j.jacl.2022.07.005_sbref0008","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/j.jacl.2014.02.013","article-title":"The National Lipid Association's Safety Task Force. An assessment by the Statin Cognitive Safety Task Force: 2014 update","volume":"8","author":"Rojas-Fernandez","year":"2014","journal-title":"J Clin Lipidol"},{"issue":"25 Suppl 2","key":"10.1016\/j.jacl.2022.07.005_bib0009","first-page":"S1","article-title":"2013 ACC\/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines","volume":"129","author":"Stone","year":"2014","journal-title":"Circulation"},{"issue":"7","key":"10.1016\/j.jacl.2022.07.005_bib0010","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1056\/NEJMoa1701131","article-title":"Cognitive function in a randomized trial of evolocumab","volume":"377","author":"Giugliano","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.07.005_bib0011","unstructured":"FDA advises of adverse effects from new cholesterol drugs. 2014. Available at https:\/\/www.wsj.com\/articles\/SB10001424052702304732804579425612487904436."},{"key":"10.1016\/j.jacl.2022.07.005_bib0012","doi-asserted-by":"crossref","first-page":"1500","DOI":"10.1056\/NEJMoa1500858","article-title":"Efficacy and safety of evolocumab in reducing lipids and cardiovascular events","volume":"372","author":"Sabatine","year":"2015","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.jacl.2022.07.005_bib0013","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1056\/NEJMoa1501031","article-title":"Efficacy and safety of alirocumab in reducing lipids and cardiovascular events","volume":"372","author":"Robinson","year":"2015","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.jacl.2022.07.005_bib0014","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1093\/eurheartj\/ehv563","article-title":"The impact of proprotein convertase subtilisin-kexin type 9 serine protease inhibitors on lipid levels and outcomes in patients with primary hypercholesterolaemia: a network meta-analysis","volume":"37","author":"Lipinski","year":"2016","journal-title":"Eur Heart J"},{"issue":"14","key":"10.1016\/j.jacl.2022.07.005_bib0015","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1056\/NEJMoa2019910","article-title":"Evolocumab in pediatric heterozygous familial hypercholesterolemia","volume":"383","author":"Santos","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jacl.2022.07.005_bib0016","doi-asserted-by":"crossref","first-page":"704","DOI":"10.3389\/fpsyg.2015.00704","article-title":"The nature and rate of cognitive maturation from late childhood to adulthood","volume":"6","author":"Cromer","year":"2015","journal-title":"Front Psychol"},{"issue":"5","key":"10.1016\/j.jacl.2022.07.005_bib0017","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/j.jacl.2018.05.007","article-title":"Efficacy, safety, and tolerability of evolocumab in pediatric patients with heterozygous familial hypercholesterolemia: Rationale and design of the HAUSER-RCT study","volume":"12","author":"Gaudet","year":"2018","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.jacl.2022.07.005_bib0018","series-title":"Statistical Power Analysis For The Social And Behavioral Sciences: Basic And Advanced Techniques","author":"Cohen","year":"1988"},{"issue":"18","key":"10.1016\/j.jacl.2022.07.005_bib0019","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1056\/NEJMoa1615664","article-title":"Evolocumab and clinical outcomes in patients with cardiovascular disease","volume":"376","author":"Sabatine","year":"2017","journal-title":"N Engl J Med"},{"issue":"17","key":"10.1016\/j.jacl.2022.07.005_bib0020","doi-asserted-by":"crossref","first-page":"2132","DOI":"10.1016\/j.jacc.2019.08.1024","article-title":"Long-term efficacy and safety of evolocumab in patients with hypercholesterolemia","volume":"74","author":"Koren","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"20","key":"10.1016\/j.jacl.2022.07.005_bib0021","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1161\/CIRCULATIONAHA.120.052358","article-title":"Cardiovascular risk factor trajectories since childhood and cognitive performance in midlife: The cardiovascular risk in young finns study","volume":"143","author":"Hakala","year":"2021","journal-title":"Circulation"},{"issue":"16","key":"10.1016\/j.jacl.2022.07.005_bib0022","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa1816454","article-title":"20-year follow-up of statins in children with familial hypercholesterolemia","volume":"381","author":"Luirink","year":"2019","journal-title":"N Engl J Med"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002100?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287422002100?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T13:38:14Z","timestamp":1761831494000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287422002100"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,9]]}},"alternative-id":["S1933287422002100"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2022.07.005","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2022,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cognitive function with evolocumab in pediatric heterozygous familial hypercholesterolemia","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2022.07.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 National Lipid Association. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}